Q4 2023 · 13F-HR
Venrock Adviser, LLCholdings as filed
Filed 2024-02-14 · accession 0001104659-24-023659
$1.46B
Reported value
36
Positions
2023-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 75525N107 | — | RAYZEBIO INC | $250.6M | 17.2% | 4,030,471 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $237.3M | 16.3% | 8,493,321 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $95.2M | 6.53% | 3,395,606 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $84.6M | 5.80% | 3,882,623 | Common | SOLE |
| 35104E100 | FDMT | 4D MOLECULAR THERAPEUTICS IN | $69.4M | 4.76% | 3,424,031 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $59.1M | 4.05% | 2,148,214 | Common | SOLE |
| 12674W109 | CABA | CABALETTA BIO INC | $58.2M | 3.99% | 2,563,952 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $51.1M | 3.50% | 2,372,714 | Common | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $50.1M | 3.44% | 4,092,731 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $40.9M | 2.80% | 2,954,902 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $34.7M | 2.38% | 7,775,760 | Common | SOLE |
| 43157M102 | — | HILLEVAX INC | $33.3M | 2.28% | 2,075,000 | Common | SOLE |
| 641871108 | — | AMBRX BIOPHARMA INC | $29.5M | 2.02% | 2,070,000 | Common | SOLE |
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $29.2M | 2.00% | 4,497,117 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $28.9M | 1.98% | 2,173,913 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $27.5M | 1.89% | 4,684,167 | Common | SOLE |
| 15102K100 | CELC | CELCUITY INC | $27.5M | 1.88% | 1,885,538 | Common | SOLE |
| 59045L106 | — | MERSANA THERAPEUTICS INC | $26.3M | 1.80% | 11,328,000 | Common | SOLE |
| 04335A105 | ARVN | ARVINAS INC | $25.8M | 1.77% | 627,788 | Common | SOLE |
| 04635X102 | CATBUSD | ASTRIA THERAPEUTICS INC | $24.8M | 1.70% | 3,225,806 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $22.8M | 1.56% | 495,983 | Common | SOLE |
| 68622P109 | ORIC | ORIC PHARMACEUTICALS INC | $22.3M | 1.53% | 2,428,385 | Common | SOLE |
| 03828A101 | APLT | APPLIED THERAPEUTICS INC | $20.9M | 1.44% | 6,250,000 | Common | SOLE |
| 877619106 | TSHA | TAYSHA GENE THERAPIES INC | $18.4M | 1.26% | 10,412,872 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC | $16.4M | 1.13% | 3,500,000 | Common | SOLE |
| 55234L105 | LYRAGBP | LYRA THERAPEUTICS INC | $13.5M | 0.93% | 2,575,593 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $10.7M | 0.73% | 998,570 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $9.6M | 0.66% | 927,706 | Common | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $7.9M | 0.54% | 353,626 | Common | SOLE |
| G3855L106 | GHRS | GH RESEARCH PLC | $7.6M | 0.52% | 1,318,327 | Common | SOLE |
| 00445A100 | — | ACELYRIN INC | $7.0M | 0.48% | 937,113 | Common | SOLE |
| 30233G209 | EYPT | EYEPOINT PHARMACEUTICALS INC | $5.8M | 0.40% | 250,000 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $4.6M | 0.31% | 3,422,397 | Common | SOLE |
| 00773U108 | ADVMCHF | ADVERUM BIOTECHNOLOGIES INC | $3.9M | 0.27% | 5,147,547 | Common | SOLE |
| 59935V107 | MIST | MILESTONE PHARMACEUTICALS IN | $1.5M | 0.11% | 925,048 | Common | SOLE |
| 68062P106 | OLMA | OLEMA PHARMACEUTICALS INC | $1.1M | 0.07% | 77,042 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.